{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:22:43Z","timestamp":1789179763926,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alcohol and Drug Abuse Research Program","award":["#2018F-ADARP"],"award-info":[{"award-number":["#2018F-ADARP"]}]},{"name":"Alcohol and Drug Abuse Research Program","award":["171"],"award-info":[{"award-number":["171"]}]},{"name":"State of Washington Initiative Measure","award":["#2018F-ADARP"],"award-info":[{"award-number":["#2018F-ADARP"]}]},{"name":"State of Washington Initiative Measure","award":["171"],"award-info":[{"award-number":["171"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Benzodiazepines (BZDs) such as oxazepam are commonly prescribed depressant drugs known for their anxiolytic, hypnotic, muscle relaxant, and anticonvulsant effects and are frequently used in conjunction with other illicit drugs including cannabis. Oxazepam is metabolized in an enantiomeric-specific manner by glucuronidation, with S-oxazepam metabolized primarily by UGT2B15 and R-oxazepam glucuronidation mediated by both UGT 1A9 and 2B7. The goal of the present study was to evaluate the potential inhibitory effects of major cannabinoids, \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD), and major THC metabolites, 11-hydroxy-\u03949-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-\u03949-tetrahydrocannabinol (11-COOH-THC), on the UGT-mediated metabolism of R- and S-oxazepam. The cannabinoids and metabolites were screened as inhibitors of R- and S-oxazepam glucuronidation in microsomes isolated from HEK293 cells overexpressing individual UGT enzymes (rUGTs). The IC50 values were determined in human liver microsomes (HLM), human kidney microsomes (HKM), and rUGTs and utilized to estimate the nonspecific, binding-corrected Ki (Ki,u) values and predict the area under the concentration\u2013time curve ratio (AUCR). The estimated Ki,u values observed in HLM for S- and R-oxazepam glucuronidation by CBD, 11-OH-THC, and THC were in the micromolar range (0.82 to 3.7 \u00b5M), with the Ki,u values observed for R-oxazepam glucuronidation approximately 2- to 5-fold lower as compared to those observed for S-oxazepam glucuronidation. The mechanistic static modeling predicted a potential clinically significant interaction between oral THC and CBD with oxazepam, with the AUCR values ranging from 1.25 to 3.45. These data suggest a pharmacokinetic drug\u2013drug interaction when major cannabinoids like CBD or THC and oxazepam are concurrently administered.<\/jats:p>","DOI":"10.3390\/pharmaceutics16020243","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T03:47:09Z","timestamp":1707277629000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid\u2013Oxazepam Drug Interactions"],"prefix":"10.3390","volume":"16","author":[{"given":"Keti","family":"Bardhi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-9298","authenticated-orcid":false,"given":"Shelby","family":"Coates","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/03602532.2017.1377223","article-title":"Metabolic profile of oxazepam and related benzodiazepines: Clinical and forensic aspects","volume":"49","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.30.11.1257","article-title":"Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9","volume":"30","author":"Court","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-199502000-00005","article-title":"(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7","volume":"5","author":"Patel","year":"1995","journal-title":"Pharmacogenetics"},{"key":"ref_4","first-page":"873","article-title":"Enhanced glucuronide conjugation of drugs in obesity: Studies of lorazepam, oxazepam, and acetaminophen","volume":"101","author":"Abernethy","year":"1983","journal-title":"J. Lab. Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1124\/dmd.113.051656","article-title":"The glucuronidation of R- and S-lorazepam: Human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs","volume":"41","author":"Uchaipichat","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.2009.03519.x","article-title":"Evidence for oxazepam as an in vivo probe of UGT2B15: Oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion","volume":"68","author":"He","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1039\/C8OB02991A","article-title":"Racemization of oxazepam and chiral 1,4-benzodiazepines. DFT study of the reaction mechanism in aqueous solution","volume":"17","author":"Hok","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00008571-199510000-00004","article-title":"Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam","volume":"5","author":"Patel","year":"1995","journal-title":"Pharmacogenetics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","article-title":"Benzodiazepine use, misuse, and abuse: A review","volume":"6","author":"Schmitz","year":"2016","journal-title":"Ment. Health Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.pharma.2009.07.001","article-title":"Benzodiazepine dependence: Focus on withdrawal syndrome","volume":"67","author":"Authier","year":"2009","journal-title":"Ann. Pharm. Fr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.31887\/DCNS.2007.9.4\/nkogan","article-title":"Cannabinoids in health and disease","volume":"9","author":"Kogan","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_12","first-page":"180","article-title":"Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency Department Visits and Overdose Deaths from Combined Use of Opioids and Benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2710.1999.00247.x","article-title":"Clinically significant pharmacokinetic drug interactions with benzodiazepines","volume":"24","author":"Tanaka","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5455\/2319-2003.ijbcp20141011","article-title":"Study of potential drug-drug interactions between benzodiazepines and four commonly used antiepileptic drugs in mice","volume":"3","author":"Shah","year":"2017","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20335","DOI":"10.1038\/s41598-019-56785-1","article-title":"A Novel Phytocannabinoid Isolated From Cannabis sativa L. With an in vivo Cannabimimetic Activity Higher Than \u03949-tetrahydrocannabinol: \u03949-Tetrahydrocannabiphorol","volume":"9","author":"Citti","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: The first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","first-page":"149","article-title":"Chemistry, metabolism, and toxicology of cannabis: Clinical implications","volume":"7","author":"Sharma","year":"2012","journal-title":"Iran. J. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1185\/030079907X167525","article-title":"Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting","volume":"23","author":"Meiri","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12630-017-0814-3","article-title":"A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery","volume":"64","author":"Levin","year":"2017","journal-title":"Can. J. Anaesth."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QAI.0b013e31811ed205","article-title":"Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep","volume":"45","author":"Haney","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pagano, C.A.-O., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., and Laezza, C. (2022). Cannabinoids: Therapeutic Use in Clinical Practice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063344"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/phar.2469","article-title":"CBD and THC: Do They Complement Each Other Like Yin and Yang?","volume":"40","author":"Pennypacker","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and \u03949-Tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/acs.chemrestox.2c00259","article-title":"Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD)","volume":"36","author":"Nasrin","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","article-title":"CYP2C-catalyzed \u03949-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin","volume":"70","author":"Bland","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.lfs.2006.12.032","article-title":"Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes","volume":"80","author":"Watanabe","year":"2007","journal-title":"Life Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/0024-3205(95)00193-A","article-title":"Metabolism of \u03949-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys","volume":"56","author":"Matsunaga","year":"1995","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/dmd.118.086074","article-title":"In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites","volume":"47","author":"Qian","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.121.000530","article-title":"Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"Patsalos","year":"2020","journal-title":"Epilepsia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.105.009100","article-title":"Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: Decreased glucuronidative activity of the UGT1A10139Lys isoform","volume":"34","author":"Dellinger","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1124\/dmd.107.017145","article-title":"Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases","volume":"35","author":"Sun","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00313","DOI":"10.1002\/prp2.313","article-title":"Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: Results of a novel anti-aromatase activity assay examining exemestane and its derivatives","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_48","first-page":"40","article-title":"Diastereoisomeric glucuronides of oxazepam. Isolation and stereoselective enzymic hydrolysis","volume":"7","author":"Ruelius","year":"1979","journal-title":"Drug Metab. Dispos."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/nar\/gkp253","article-title":"IC50-to-Ki: A web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding","volume":"37","author":"Cer","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/bdd.2241","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: Implications for drug-drug interactions","volume":"41","author":"Wang","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108459","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_52","unstructured":"(2023, October 04). In Vitro Drug Interaction Studies Cytochrome P450 Enzymes and Transporter Mediated Drug Interactions, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions#:~:text=Guidance%20for%20Industry-,In%20Vitro%20Drug%20Interaction%20Studies%20%E2%80%94%20Cytochrome%20P450%20Enzyme%2D%20and%20Transporter,Guidance%20for%20Industry%20January%202020&text=This%20final%20guidance%20is%20intended,of%20an%20investigational%20drug%20product."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12248-020-00513-5","article-title":"Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J."},{"key":"ref_54","first-page":"387","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jps.2600630705","article-title":"Physiochemical properties, solubility, and protein binding of \u03949-tetrahydrocannabinol","volume":"63","author":"Garrett","year":"1974","journal-title":"J. Pharm. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0379-0738(02)00023-3","article-title":"Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-\u03949-carboxy tetrahydrocannabinol glucuronide","volume":"126","author":"Skopp","year":"2002","journal-title":"Forensic Sci. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1373\/clinchem.2008.122119","article-title":"\u03949-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC","volume":"55","author":"Schwilke","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/JCP.0000000000001427","article-title":"Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People","volume":"41","author":"Anderson","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00204-020-02765-8","article-title":"Human variability in isoform-specific UDP-glucuronosyltransferases: Markers of acute and chronic exposure, polymorphisms and uncertainty factors","volume":"94","author":"Kasteel","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","article-title":"Randomized, Double-Blind, Placebo-Controlled Study about the Effects of Cannabidiol (CBD) on the Pharmacokinetics of \u03949-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract","volume":"27","author":"Nadulski","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jat\/16.5.276","article-title":"Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana","volume":"16","author":"Huestis","year":"1992","journal-title":"J. Anal. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF00427095","article-title":"Clinical effects and plasma levels of \u03949-tetrahydrocannabinol (\u03949-THC) in heavy and light users of cannabis","volume":"74","author":"Lindgren","year":"1981","journal-title":"Psychopharmacology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed. Environ. Mass. Spectrom."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/chir.530030313","article-title":"N,N-dimethylcarbamyl derivatives of oxazepam","volume":"3","author":"Yang","year":"1991","journal-title":"Chirality"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:20Z","timestamp":1760104580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["pharmaceutics16020243"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16020243","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}